Volume 89 Issue 5 | pp. 30-33
Issue Date: January 31, 2011

RNAi Growing Pains

Roche’s exit cast a pall, but others claim progress in developing RNAi-based drugs
Department: Business
Keywords: RNAi, siRNA, Roche, Alnylam, Novartis, Marina Biotech, Dicerna, RXi

When Roche announced in November 2010 that it would jettison research in the field of RNA interference, industry observers were stunned. After all, it had been among the few big pharma companies putting significant cash into what many considered the most promising new pharmaceutical technology in recent years.

But Roche’s exit was only one sign of problems for companies developing RNAi-based drugs. Several biotech firms failed to meet their goal of signing a . . .

To view the rest of this content, please log in with your ACS ID.



 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society